Dabigatran etexilate mesylate is a direct thrombin inhibitor used clinically as a novel oral anticoagulant. Its mechanism of action involves reversible and potent competitive binding to the fibrin-specific site of thrombin, thereby blocking fibrin formation and inhibiting thrombus development.
GMP US-DMF
